Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeated-dose Zevalin after salvage chemotherapy for relapsed or refractory aggressive B-cell lymphoma
2007-003539-22Phase 2Terminated
- Sponsor
- Gimurell
- Start
- Dec 2007
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in diffuse large B-cell lymphoma (DLBCL) and aggressive B-cell lymphoma, sponsored by Gimurell. Primary endpoint: 1-year event-free survival. Started Dec 2007; status: terminated.
02
Drugs
ibritumomab tiuxetan
03
Conditions
diffuse large B-cell lymphoma (DLBCL)aggressive B-cell lymphoma
Beyond the preview
Go deeper on 2007-003539-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003539-22.